Takeda Pharmaceutical Company Limited (TYO:4502)
5,843.00
+27.00 (0.46%)
Oct 9, 2026, 3:30 PM JST
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,029 employees as of March 31, 2026. The number of employees decreased by 426 or -0.90% compared to the previous year. That makes Takeda Pharmaceutical Company the 762nd largest employer in the world and 70th in Japan.
Employees
47,029
Change (1Y)
-426
Growth (1Y)
-0.90%
Revenue / Employee
98.21M JPY
Profits / Employee
-3.48M JPY
Market Cap
9.33T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 47,029 | -426 | -0.90% |
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Eisai | 10,543 |
| Shionogi & | 6,223 |
| Sumitomo Pharma | 4,980 |
| Tsumura & Co. | 4,923 |
| Towa Pharmaceutical | 4,923 |
| Sawai Group Holdings | 3,630 |
| Nippon Shinyaku | 2,309 |
| Kissei Pharmaceutical | 1,786 |
Takeda Pharmaceutical Company News
- 10 days ago - Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib - TheFly
- 10 days ago - Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib - TheFly
- 10 days ago - Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial - Nasdaq
- 10 days ago - Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial - Nasdaq
- 10 days ago - Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill - Business Wire
- 11 days ago - Keros Therapeutics to receive $20M development milestone payment from Takeda - TheFly
- 11 days ago - Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium - Business Wire
- 17 days ago - Roche Proposes Former Takeda CEO Christophe Weber For Board Role - Nasdaq